Potential prognostic parameters and real-world data in patients with primary central nervous system lymphoma: a new brick on the old ones

Yıl 2023, Cilt: 9 Sayı: 5 - September 2023, 1157 - 1165, 04.09.2023

Tuba Ersal , Vildan Ozkocaman , İbrahim Ethem Pınar , Cumali Yalçın , Bedrettin Orhan , Ömer Candar , Sinem Çubukçu , Tuba Güllü Koca , Rıdvan Ali , Fahir Özkalemkaş

https://doi.org/10.18621/eurj.1267903

Öz

Objectives: We aimed to evaluate the potential prognostic factors of patients with primary central nervous system lymphoma (PCNSL).

Methods: Thirty-two patients with PCNSL were retrospectively analyzed.

Results: All the patients received high doses of methotrexate-based chemotherapy as the first-line treatment. Overall survival was 30.0 ± 7.2 months. Those with partial response and without response had a higher risk of mortality. The increased leukocyte and neutrophil levels were associated with high mortality. Besides, the SIIL as a product of the systemic immune inflammation (SII) and lactate dehydrogenase (LDH); the SIRIL as a product of systemic immune response index (SIRI) and LDH; and the NLL as a product of neutrophil-lymphocyte ratio and LDH were taken into consideration for the first time for the purposes of the present study. Elevated NLL, SIIL, and SIRIL indexes were associated with mortality. Elevated SIIL level, radiotherapy, and partial and no response were the independent predictors of mortality on the basis of the multivariable regression model including the risk factors associated with mortality.

Conclusions: SIIL, SIRIL and NLL are prognostic factors in PCNSL. Determining the prognostic factors and risk profile may predict the requirement for more intensive treatment, especially in young patients at high risk.

Anahtar Kelimeler

Primary central nervous system lymphoma, prognostic score, parameters

Kaynakça

• 1. Villano JL, Koshy M, Shaikh H, Dolecek TA, McCarthy BJ. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105:1414-8.
• 2. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266-72.
• 3. Bessell EM, Graus F, Lopez-Guillermo A, Lewis SA, Villa S, Verger E, et al. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys 2004;59:501-8.
• 4. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24:5711-5.
• 5. Zheng Z, Zhou L, Gao S, Yang z, Yao J, Zheng S. Prognostic role of C-reactive protein in hepatocellular carcinoma: a systematic review and meta-analysis. Int J Med Sci 2013;10:653-64.
• 6. Huang QT, Zhou L, Zeng WJ, eMa QQ, Wang W, Zhong M, t al. Prognostic significance of neutrophil-to-lymphocyte ratio in ovarian cancer: a systematic review and meta-analysis of observational studies. Cell Physiol Biochem 2017;41:2411-8.
• 7. Cummings M, Merone L, Keeble C, Burland L, Grzelinski M, Sutton K, et al. Preoperative neutrophil:lymphocyte and platelet:lymphocyte ratios predict endometrial cancer survival. Br J Cancer 2015;113:311-20.
• 8. Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer 2016;122:2158-67.
• 9. Sun Y, Li W, Li AJ, Su H, Yue J, Yu J. Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative, HER2-positive breast cancer patients. Cancer Manag Res 2019;11:3153-62.
• 10. Huang H, Liu Q, Zhu L, Zhang Y, Lu X, Wu Y, et al. Prognostic value of preoperative systemic immune-inflammation index in patients with cervical cancer. Sci Rep 2019;9:3284.
• 11. Zhu M, Chen L, Kong X, Wang X, Fang Y, Li X, et al. The systemic inflammation response index as an independent predictor of survival in breast cancer patients: a retrospective study. Front Mol Biosci 2022;9:856064.
• 12. Nozoe T, Kohno M, Iguchi T, Mori E, Maeda T, Matsukuma A, et al. The prognostic nutritional index can be a prognostic indicator in colorectal carcinoma. Surg Today 2012;42:532-5.
• 13. Mohri Y, Inoue Y, Tanaka K, Hiro J, Uchida K, Kusunoki M. Prognostic nutritional index predicts postoperative outcome in colorectal cancer. World J Surg 2013;37:2688-92.
• 14. Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer 2012;106:1439-45.
• 15. Abrey LE, Batchelor TT, Ferreri AJM, Gospodarowicz M, Pulczynki E, Zucca E, et al. Report of an International workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-43.
• 16. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
• 17. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
• 18. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol 2017;14:399-416.
• 19. Li KJ, Xia XF, Su M, Zhang H, Chen WH, Zou GL, et al. Predictive value of lymphocyte-to-monocyte ratio (LMR) and neutrophil-to-lymphocyte ratio (NLR) in patients with oesophageal cancer undergoing concurrent chemoradiotherapy. BMC Cancer 2019;19:1004.
• 20. Reddy JP, Hernandez M, Gunther JR, Dabaja BS, Martin GV, Jiang W, et al. Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. Br J Haematol 2018;180:545-9.
• 21. Bento L, Díaz-López A, Barranco G, Martin-Moreno AM, Baile M, Martin A, et al. New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta-2 microglobulin in patients with diffuse large B-cell lymphoma treated with R-CHOP: Spanish Lymphoma Group Experience (GELTAMO). Br J Haematol 2020;188:888-97.
• 22. Cencini E, Fabbri A, Sicuranza A, Bocchia M. Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma. Leuk Res 2019;77:5-7.
• 23. Tan KM, Chia B, Lim JQ, Khoo LP, Cheng CL, Tan L, et al. A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: a multicenter study. Sci Rep 2019;9:14961.
• 24. Mueller CG, Boix C, Kwan WH, Daussy C, Fournier E, Friedman WH, et al. Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation. J Leukoc Biol 2007;82:567-75.
• 25. Luo Q, Yang C, Fu C, Wu W, Wei Y, Zou L. Prognostic role of blood markers in primary central nervous system lymphoma patients treated with high-dose methotrexate-based therapy. Front Oncol 2021;11:639644.
• 26. Suzuki K, Aiura K, Ueda M, Kitajima M. The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents. Pancreas 2004;29:132-40.
• 27. Feng Y, Liu Y, Zhong M, Wang L. Complete blood count score model predicts inferior prognosis in primary central nervous system lymphoma. Front Oncol 2021;11:618694.
• 28. Guo W, Cai S, Zhang F, Shao F, Zhang G, Zhou Y, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. Thorac Cancer 2019;10:761-8.
• 29. Mirili C, Paydas S, Kapukaya TK, Yılmaz A. Systemic immune-inflammation index predicting survival outcome in patients with classical Hodgkin lymphoma. Biomark Med 2019;13:1565-75.
• 30. Schorb E, Kasenda B, Atta J, Kaun S, Morgner A, Hess G, et al. Prognosis of patients with primary central nervous system lymphoma after high-dose chemotherapy followed by autologous stem cell transplantation. Haematologica 2013;98:765-70.
• 31. Jahr G, Broi MD, Holte H, Jr., Beiske K, Meling TR. Evaluation of memorial Sloan-Kettering Cancer Center and International Extranodal Lymphoma Study Group prognostic scoring systems to predict overall survival in intracranial primary CNS lymphoma. Brain Behav 2018;8):e00928.
• 32. Ghesquières H, Ferlay C, Sebban C, Perol D, Bosly A, Casasnovas O, et al. Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Ann Oncol 2010;21:842-50.
• 33. Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, et al. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res 2012;18:1146-55.
• 34. Grommes C, DeAngelis LM. Primary CNS lymphoma. J Clin Oncol 2017;35:2410-8.
• 35. Sinicrope K, Batchelor T. Primary central nervous system lymphoma. Neurol Clin 2018;36:517-32.
• 36. Hoang-Xuan K, Bessell E, Bromberg J, Hottinger AF, Preusser M, Ruda R, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol 2015;16:e322-32.
• 37. Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys 1998;41:615-20.
• 38. Ferreri AJ, Reni M, Pasini F, Calderoni A, Tirelli U, Pivrik A, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology 2002;58:1513-20.
• 39. Yuan XG, Huang YR, Yu T, Xu Y, Liang Yun, Zhang XH, et al. Primary central nervous system lymphoma in China: a single-center retrospective analysis of 167 cases. Ann Hematol 2020;99:93-104.
• 40. Ouyang T, Wang L, Zhang N, Zhang Z, Xiong Y, Li M, et al. Clinical characteristics, surgical outcomes, and prognostic factors of intracranial primary central nervous system lymphoma. World Neurosurg 2020;139:e508-16.
• 41. Deng X, Xu X, Lin D, Zhang X, Yu L, Sheng H, et al. Real-world impact of surgical excision on overall survival in primary central nervous system lymphoma. Front Oncol 2020;10:131.
• 42. Jung J, Lee H, Yun T, Lee E, Moon H, Joo J, et al. Prognostic role of the neutrophil-to-lymphocyte ratio in patients with primary central nervous system lymphoma. Oncotarget 2017;8:74975-86.
• 43. Bromberg JEC, Issa S, Bakunina K, Minnema MC, Seute T, Durian M, et al. Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. Lancet Oncol 2019;20:216-28.
• 44. Houillier C, Taillandier L, Lamy T, Chinot O, Molucon-Chabrot C, Soubeyran P, et al. Whole brain radiotherapy (WBRT) versus intensive chemotherapy with haematopoietic stem cell rescue (IC + HCR) for primary central nervous system lymphoma (PCNSL) in young patients: An Intergroup Anocef-Goelams Randomized Phase II Trial (PRECIS). Blood. 2016;128:782.